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Abstract
There is a need for transplantable murine models of ovarian
high-grade serous carcinoma (HGSC)with regard tomutations in
the human disease to assist investigations of the relationships
between tumor genotype, chemotherapy response, and immune
microenvironment. In addressing this need, we performedwhole-
exome sequencing of ID8, the most widely used transplantable
model of ovarian cancer, covering 194,000 exomes at a mean
depth of 400 with 90% exons sequenced >50. We found no
functional mutations in genes characteristic of HGSC (Trp53,
Brca1, Brca2, Nf1, and Rb1), and p53 remained transcriptionally
active. Homologous recombination in ID8 remained intact in
functional assays. Further, we found nomutations typical of clear
cell carcinoma (Arid1a, Pik3ca), low-grade serous carcinoma
(Braf), endometrioid (Ctnnb1), or mucinous (Kras) carcinomas.
Using CRISPR/Cas9 gene editing, we modeled HGSC by gener-
ating novel ID8 derivatives that harbored single (Trp53–/–) or
double (Trp53–/–;Brca2–/–) suppressor gene deletions. In these
mutants, loss of p53 alone was sufficient to increase the growth
rate of orthotopic tumors with significant effects observed on the
immune microenvironment. Specifically, p53 loss increased
expression of the myeloid attractant CCL2 and promoted the
infiltration of immunosuppressive myeloid cell populations into
primary tumors and their ascites. In Trp53–/–;Brca2–/– mutant
cells, we documented a relative increase in sensitivity to the PARP
inhibitor rucaparib and slower orthotopic tumor growth
compared with Trp53–/– cells, with an appearance of intratumoral
tertiary lymphoid structures rich in CD3þ T cells. This work
validates new CRISPR-generated models of HGSC to investigate
its biology and promote mechanism-based therapeutics disco-
very. Cancer Res; 76(20); 6118–29. 2016 AACR.
Introduction
Ovarian high-grade serous carcinoma (HGSC) is the common-
est subtype of human ovarian cancer (1), and long-term survival
remains poor (2). Mutation in TP53 is essentially universal (3, 4),
whereas germline mutation in BRCA1 or BRCA2 is observed in
approximately 15% cases (5, 6). These mutations impair the
ability to repair DNA double-strand breaks (DSB) via homolo-
gous recombination (HR). The Cancer Genome Atlas consortium
suggested that HR defects may be present in approximately 50%
HGSC through a variety of additional mechanisms, including
somatic BRCA1/2mutation and epigenetic loss of BRCA1 expres-
sion (4). Another key development has been the finding that
HGSCmay arise in the fimbriae of the fallopian tube, rather than
the ovarian surface epithelium (OSE; ref. 7). Early serous tubal
intra-epithelial carcinoma (STIC) lesions in the tubal fimbriae are
observed in up to 10% of women with germline BRCA1/2muta-
tions undergoing prophylactic salpingo-oophorectomy (8).
Although a tubal origin of HGSC is widely accepted (9), STIC
lesions are only seen in around half of HGSC cases (10). Recent
data from mouse models (11, 12) and clinical HGSC samples
(13) suggest that the ovary itself may still be crucial in the
pathogenesis of HGSC, and it is possible that there could be
more than one origin of this tumor.
The absence of reliable murine models has been a major
impediment in HGSC research (14). This is particularly impor-
tant for investigation of the immune microenvironment. The
presence of tumor-infiltrating CD8 T lymphocytes (TIL) and
tertiary intraepithelial lymphoid aggregates are both associated
with improved prognosis in HGSC (15, 16), whereas intratu-
moral immunosuppressive myeloid and lymphoid cells (17,
18) are associated with poor prognosis. However, it is unclear
whether or how specific genomic events in HGSC influence the
immune microenvironment.
The ID8 model, first described in 2000 (19), remains the
only transplantable murine model of ovarian cancer routinely
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available. Whole ovaries from C57Bl/6 mice were trypsin-
digested, and the dissociated cells passaged in vitro, initially in
the presence of EGF. After approximately 20 passages, cells lost
contact inhibition, and ten separate clones were derived, of which
ID8 is the most widely used. Following intraperitoneal injection
of ID8 in syngeneic mice, diffuse peritoneal carcinomatosis, with
blood-stained ascites, develops in approximately 110 days (19).
Over 100 publications have utilized the ID8model, but none has
characterized it in light of current understanding of human
ovarian cancer biology.
Here, we show that parental ID8 lacks mutations in Trp53,
Brca1, and Brca2, and demonstrates HR competence in functional
assays. We have used CRISPR/Cas9 gene editing technology to
generate single (Trp53) and double (Trp53;Brca2) knockout deri-
vatives of ID8 and evaluated their utility as a model of human
HGSC. In particular, we show that loss of individual genes results
in significant alterations in immune cell infiltration into the
tumor microenvironment.
Materials and Methods
Cell culture
ID8 cells, obtained from Dr. Katherine Roby (University of
Kansas Medical Center, Kansas City, KS), were cultured in DMEM
supplemented with 4% fetal calf serum, 100 mg/mL penicillin,
100 mg/mL streptomycin, and ITS (5 mg/mL insulin, 5 mg/mL
transferrin, and 5 ng/mL sodium selenite). As ID8 was obtained
directly from their original source, separate short tandem repeat
validation was not performed. For cytotoxicity assays, cells were
plated onto 24 well plates (3  103 cells/well) in triplicate.
Survival was assessed by MTT assay (Nutlin-3) or sulphorhoda-
mine B assay (rucaparib) after 72 hours.
Next-generation sequencing
Whole-exome sequencing and analysis were performed by
Beckman Coulter Genomics. Full details are given in Supplemen-
tary Methods. Summary results are presented in Supplementary
Tables S1 to S3. Primary sequencing data (BAM and VCF files) are
available in the ArrayExpress database (http://www.ebi.ac.uk/
arrayexpress) under accession number E-MTAB-4663.
Sanger sequencing
Confirmatory Sanger sequencing of exons 2 to 9 of Trp53 was
also performed on genomic DNA extracted from107 parental ID8
cells in log-growth phase as well as from five separate ID8-
microdissected tumors extracted from female C57Bl/6 mice after
110 days of intraperitoneal growth.
CRISPR/Cas9 and selection
Two open-access software programs, CHOPCHOP (https://
chopchop.rc.fas.harvard.edu/) and CRISPR design (http://
crispr.mit.edu/), were used to design guide RNAs (gRNA) targeted
to Trp53 exon 5 and Brca2 exon 3. Three guides were designed per
gene. Annealed oligonucleotides were ligated into BbsI-linearized
pSpCas9(BB)-2A-Puro [PX459 (20), gifts from Feng Zhang via
Addgene]. Version 1 (Addgene # 48139) was employed for Trp53
deletion and version 2.0 (Addgene # 62988) for Brca2. All
plasmids were sequenced to confirm successful ligation.
ID8 cells (4  105) were plated overnight in antibiotic-free
medium, and transfected with 4 mg PX459 using Lipofectamine
2000, selected under puromycin (2.5 mg/mL) for 48 hours
and plated onto 96-well plates (10 cells/mL). Single-cell colonies
were expanded for DNA extraction, protein extraction, and
cryopreservation.
PCR primers spanning potential sites of deletionwere designed
(Trp53: F 50-cttccctcacattcctttcttg-30; R 50-gctgttaaagtagaccctgggc-30,
Brca2: F 50-catggagggagtcacctttg-30, R 50-gctctggctgtctcgaactt-30).
Clones with large PCR deletions were selected for subsequent
analysis. Remaining clones were screened using the Surveyor
Nuclease Assay (Integrated DNA Technology). Mutations were
confirmed by Sanger sequencing. All sequence alignment was
performed using MAFFT version 7 (http://mafft.cbrc.jp/).
Immunoblot and cytokine array
Note that 15mgof total proteinwas electrophoresed at 140V for
1 hour, transferred onto nitrocellulose, and blocked in 5%nonfat
milk. Antibodies usedwere as follows: p53 (CM5,Novacastra and
Ab26, Abcam) and b-actin (Sigma; A1978). Membranes were
exposed on a Chemi-doc MP (Biorad) with ECL (b actin) and
ECL prime (p53). For array experiments, 5 mL supernatant was
collected from 106 cells plated for 16 hours on a 10-cm plate, and
centrifuged (2,000 rpm for 5minutes).Mouse Cytokine Antibody
Array C1 (C-series) was blotted according to the manufacturer's
instructions (RayBiotech, Inc.).
Quantitative reverse transcriptase PCR
RNA was extracted from 3 105 cells in log-growth phase, and
2 mg was reverse transcribed (Applied Biosystems High Capacity
Reverse Transcription Kit). cDNA (50 ng)was amplified using 10x
iTaq qRT-PCR master mix (Biorad), 20X primer probe mix in a
total of 20 mL under the following cycle parameters: 2 minutes:
50C, 10minutes: 95C, 40X (15 seconds: 95C; 1minute: 60C).
All qRT-PCR primers were purchased from Applied Biosystems
and Trp53 custom made from Sigma Aldrich: F 50-catcacctcactg-
catggac-30, R 50-cttcacttgggccttcaaaa-30, probe 50-ccccaggatgttgag-
gagt-30. Values were normalized to Rpl-34.
gH2AX/Rad51 assay
Cells were seeded on coverslips and treated with rucaparib (10
mmol/L for 24 hours) or irradiated (10 Gy), permeabilized with
0.2% Triton (Sigma) in PBS for 1 minute, then fixed in 3%
paraformaldehyde, and 2% sucrose for 10 minutes. Cells were
stainedwith anti-gH2AX antibody (Millipore) and costainedwith
anti-Rad51 (Santa Cruz Biotechnology) antibody for 45 minutes
at 37C. Cells were costained with DAPI. Coverslips were
mounted on slides and images captured using a Zeiss 710 con-
focal microscope and foci counted using ImageJ software. Cells
were deemed HR competent if the number of Rad51 foci more
than doubled in the presence of DNA DSB damage (2-fold
increase in number of gH2AX foci) as previously described (21).
In vivo experiments
All experiments were complied with the UK welfare guidelines
(22) and were conducted under specific personal and project
license authority. Cells (5  106) were inoculated intraperitone-
ally in 6- to 8-week-old female C57Bl/6 mice (Charles River
Laboratories). Mice were monitored regularly and killed upon
reaching UK Home Office limits. All decisions about animal
welfare and experiment endpoints were made by one of us (D.
Athineos) independently of main study investigators to prevent
bias. Asciteswas collected, and all visible tumor deposits dissected
out. Half of tumor material was snap frozen (dry ice) and half
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fixed in neutral-buffered 4% paraformaldehyde. Sections (5 mm)
from formalin-fixed paraffin-embedded tumors were stained
(Dako Autostainer, Dako) and quantified as detailed in Supple-
mentary Methods.
Ascites preparation, tumor disaggregation, and flow cytometry
Ascites was centrifuged (2,200 rpm, 10 minutes) and superna-
tant stored at –80C. The cell pellet was treatedwith red blood cell
lysis buffer (Sigma Aldrich—5 minutes, room temperature),
resuspended in 10 mL PBS, recentrifuged, and stored at –80C
inFBS/10%DMSO. Solid tumor deposits in ice-cold PBS/protease
inhibitor solution were dissected into pieces less than 1 mm
diameter using a scalpel and digested at 37C for 30 minutes
(0.012% w/v collagenase type XI, 0.012% w/v dispase, 0.25%
Trypsin in 0.1% BSA in RPMI.) Note that 10 mL of 0.1% BSA/
RPMI was added, and the tubes shaken vigorously followed by
100-mm filtration. Cells were centrifuged for 5 minutes at 1,500
rpm, resuspended in PBS containing 5% FBS, and then counted.
Flow cytometry and gating strategies are presented in Supplemen-
tary Methods.
Results
Characterization of parental ID8 in vitro and in vivo
To assess the genomic landscape of ID8, we undertook whole-
exome sequencing, covering approximately 194,000 exons at a
mean depth of 400 with 90% exons sequenced >50. Approx-
imately 6,000 variants were identified, the vast majority of which
were nonfunctional. Functional alterations (nonsynonymous
coding, stop-gain, and frameshift) were identified in approxi-
mately 100 genes, the large majority of which were nonsynon-
ymous coding (See Supplementary Tables S1–S3 for summary
and list of all functional alterations). However, we were unable to
identify any functional mutations in genes characteristic of HGSC
(Trp53, Brca1, Brca2, Nf1, Rb1), and the absence of Trp53 muta-
tions was confirmed by Sanger sequencing (data not shown). In
addition, mutations typical of clear cell (Arid1A, Pik3ca), low-
grade serous (Braf), endometrioid (Ctnnb1), andmucinous (Kras)
carcinomas were also notably absent. We did identify a mutation
inAdamts3 (c.1089C>T; pV199I)—a recent analysis of The Cancer
Genome Atlas (TCGA) data identified thatmutations inADAMTS
genes were associated with platinum sensitivity as well as
improved progression-free and overall survival in HGSC (23). In
addition, mutation in Gabra6 (c.347T>G; pE22D) was identified.
GABRA6 was one of the genes mutated at statistically significant
frequency in TCGA analysis—however, transcription was absent
in all TCGA tumors, suggesting that GABRA6 mutation is of
minimal clinical relevance (4).
Given the centrality of TP53 mutations in HGSC, we also
assessed p53 function in ID8. There was a robust increase in
p53 protein following treatment with cisplatin and the MDM2
inhibitor Nutlin-3 (Fig. 1A), with marked increases in Cdkn1A
(p21) transcription within 4 hours of cisplatin treatment (Fig.
1B), indicating that p53 remains transcriptionally active. Sanger
sequencing of intraperitoneal ID8 tumors showed no Trp53
mutation in any tumor, including common hotspot mutations
sites (R172, Y217, R245, R270—Fig. 1C), whereas immuno-
histochemistry (IHC) confirmed a wild-type pattern of p53
expression (Fig. 1D). IHC examination of typical HGSC mar-
kers indicated that tumors were strongly and diffusely positive
for WT1, but negative for Pax8 (Fig. 1D).
The whole-exome sequencing data identified no functional
abnormalities in Brca1, Brca2, or other HR genes. We confirmed
that parental ID8 cells were able to formRad51 foci in response to
DNA DSB damage induced by irradiation as well as the PARP
inhibitor rucaparib (Fig. 1E), and fulfilled the criteria of compe-
tent HR as previously described (21). Together, these data suggest
that parental ID8 is poorly representative of human HGSC.
CRISPR/Cas9-mediated Trp53 gene editing
Three separate gRNA constructs targeted to exon 5of Trp53 (Fig.
2A) were cloned into the PX459 plasmid. Following transfection
and screening (Fig. 2B and C), clones were derived from all three
guides (F3—guide G; A2—guide K; C7 andM20—guide R), all of
which contained bi-allelic deletions in Trp53 exon 5 (Supplemen-
tary Fig. S1), ranging from4bp (cloneM20) to 280 bp (clone A2).
All four null clones showed absent basal p53 expression by
immunoblot (Fig. 2D), with significantly reduced basal transcrip-
tion of Trp53 (Fig. 2E), Cdkn1a, and Bax (Fig. 2F). There was also
no increase in p53 expression following treatment with cisplatin
or Nutlin-3 (Fig. 2G), nor an increase in Cdkn1a transcription
following cisplatin (Fig. 2H). Finally, there was a significant
reduction in cell death induced by Nutlin-3 in all four clones
compared with parental ID8 (Fig. 2I). These results collectively
indicate that all four Trp53/ clones are functionally p53 defi-
cient. We also isolated control clones that had been exposed to
CRISPR plasmids (both empty PX459 and PX459 encoding Trp53
gRNA) but did not contain any Trp53 mutation on sequencing.
These cells retained p53 transcriptional activity that was indistin-
guishable from parental ID8 (Supplementary Fig. S2).
We then assessed intraperitoneal growthof theTrp53/ clones.
Following intraperitoneal injection into female C57Bl/6 mice,
there was a highly significant reduction in time to reach prede-
fined humane endpoints with all four clones. Median survival
time ranged from42 to 57days (Fig. 3A), comparedwith 101days
for mice bearing either parental ID8 or CRISPR control cells (P <
0.0001 for all clones compared with both parental ID8 and
CRISPR controls). There was no difference in volume of ascites
between parental ID8, CRISPR control, or Trp53/ tumors (Fig.
3B). Macroscopically, the patterns of growth and spread within
the peritoneal cavity were similar, although there was some
evidence of increased numbers of miliary deposits on the peri-
toneum and diaphragm in Trp53/ tumors (Fig. 3C). By IHC, we
confirmed the absence of p53 expression in Trp53/ tumors
(Fig. 3D). Trp53/ tumors retained strong positivity forWT1, but
remained negative for Pax8 (Fig. 3E).We also observed significant
increases in Ki67 expression in Trp53/ tumors (Fig. 3F), con-
sistent with their more rapid intraperitoneal growth.
Generation of double Trp53/;Brca2/ mutants
We next targeted exon 3 of Brca2, which encodes the PALB2
binding domain (Fig. 4A). Using the F3 Trp53/ clone, we
generated three separate double Trp53/;Brca2/ clones (1.4,
2.14, and3.15), eachderived fromadifferent guide, and eachwith
distinct deletions (Supplementary Fig. S3). All three Trp53/;
Brca2/ clones fulfilled the criteria for defective HR (Fig. 4B;
ref. 21) and lost the ability to form Rad51 foci in response to
irradiation (Fig. 4C; Supplementary Fig. S4). In addition, all
clones were significantly more sensitive to PARP inhibitor–medi-
ated cytotoxicity (Fig. 4D). By contrast, control cells (Trp53/
cells exposed to PX459 encoding Brca2 gRNA but with no Brca2
deletion) had the same sensitivity to rucaparib as parental ID8
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Figure 1.
ID8 retains wild-type p53 function and demonstrates competent homologous recombination. A, expression of p53 was assessed in ID8 cells following treatment for
up to 8 hours with 10 mmol/L cisplatin (left) or 10 mmol/L Nutlin-3 (right). B, transcription of p53 target Cdkn1a in ID8 cells following treatment for up to
8 hours with 10 mmol/L cisplatin was assessed by quantitative reverse-transcriptase PCR, normalized to Rpl34. Data represent mean  SD (n ¼ 3) plotted
relative to untreated cells (t ¼ 0 hours). C, representative chromatograms of Sanger sequencing of p53 from parental ID8 tumors harvested after 110 days
intraperitoneal growth in female C57Bl/6 mice, demonstrating no mutations at critical hotspot mutations sites at residues 172, 217, 245, and 270—the equivalent
human codons are shown in parentheses below. D, ID8 tumors, fixed in 4% neutral-buffered formalin, were stained for p53, WT1, and PAX8. Bars,
100 mm. E, ID8 cellswere irradiated (10Gy) or treatedwith rucaparib (10 mmol/L for 24 hours),fixed and stained for gH2AX and RAD51, and counterstainedwith DAPI.
RAD51 foci were counted in up to 30 untreated and rucaparib-treated cells. Bars, mean ( SD) RAD51 foci per cell; dotted line, two-fold increase in
RAD51 foci/cell relative to untreated cells, suggestive of functional homologous recombination (21).
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Figure 2.
Generation and evaluation of Trp53/ ID8 cells using CRISPR/Cas9. A, design of three gRNA sequences, targeted to exon 5 of Trp53 (top). Nucleotides in red
represent PAM sequences. Schematic representation of p53 protein (bottom). Numbers represent amino acid positions. Amino acids encoded by exon 5
aremarked in red.B, representative PCR of 1 kb region spanning Trp53 exon 5 from genomic DNA extracted from ID8 and 15 single cell clones transfectedwith PX459
expressing gRNA K.  , clones with demonstrable deletions. C, representative Surveyor Nuclease Assay performed on ID8 and 11 single cell clones transfected with
PX459 expressing Trp53 gRNA K as described in Material and Methods.  , clones with mismatch suggestive of nucleotide deletion. D, expression of p53 was
assessed in parental ID8 and four Trp53/ clones by immunoblot. E, transcription of Trp53 was assessed in parental ID8 and four Trp53/ clones by quantitative
reverse-transcriptase PCR, normalized to Rpl34. Bars, mean  SD (n ¼ 3) plotted relative to parental ID8. F, transcription of p53 target genes Cdkn1a and Bax was
assessed in parental ID8 and Trp53/ clones by quantitative reverse-transcriptase PCR, normalized to Rpl34. Bars, mean  SD (n ¼ 3) plotted relative to
parental ID8. G, expression of p53 in ID8 and Trp53/ clones before and after cisplatin (10 mmol/L, 8 hours, left) and Nutlin-3 (10 mmol/L, 2 hours, right). H, fold
increase in Cdkn1a transcription in ID8 and Trp53/ clones following cisplatin treatment (10 mmol/L, 8 hours). Bars, mean  SD (n ¼ 3); dotted line, baseline
transcription in each cell population. I, ID8 and Trp53/ clones were treated with 10 mmol/L Nutlin-3 and cell survival assessed by MTT after 72 hours.
Bars, cell survival (mean  SD, n ¼ 3) relative to untreated cells.
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Figure 3.
Loss of p53 increases rate of intraperitoneal growth of ID8 tumors. Cells (5  106) were injected intraperitoneally into female C57Bl/6 mice in groups of six. Mice
were killed when they reached humane endpoints. Ascites was taken from all mice and measured. Each point on histoscore plot represents mean score for
multiple deposits (median 5; range, 1–17) per animal normalized to tumor area. A, loss of p53 significantly increases rate of intraperitoneal growth (P < 0.0001 for all
Trp53/ clones compared with both parental ID8 and CRISPR control cells). Data from four ID8 parental groups (total n ¼ 24) and two groups each of
CRISPR control and Trp53/ F3 (total n ¼ 12) are plotted. B, loss of p53 does not alter volume of ascites at humane endpoint. C, loss of p53 increases number of
tumor deposits on peritoneal (white box) and subdiaphragmatic (arrows) surfaces. Representative images from at least three mice per genotype. D, loss of p53
expressionwas confirmed by quantitative IHC in Trp53/ tumors.  , P <0.01. E, no change inWT1 and PAX8 expression following p53 loss. F, loss of p53 expression
significantly increases intraperitoneal tumor proliferation, as measured by Ki67 staining.  , P < 0.0001.
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and F3 Trp53/, and were HR competent by Rad51 assay (data
not shown).
We also assessed intraperitoneal growth of Trp53/;Brca2/
clones. When analyzed individually, there was no difference in
mouse survival between Trp53/ F3 tumors and any of the
double null tumors (Fig. 4E). However, when analyzed collec-
tively, there was a small, but significant, increase in survival: mice
bearing Trp53/;Brca2/ tumors survived 10 days longer than
Trp53/ F3 tumors (57 vs. 47 days; P < 0.01; Supplementary Fig.
S5). In addition,mice had significantly lower ascites volumes than
either parental or Trp53/ tumors (Fig. 4F). There were large
diaphragmatic and peritoneal deposits, and ascites was consis-
tently less hemorrhagic (Supplementary Fig. S6). Ki67 histoscores
were significantly higher than ID8 parental tumors (not shown)
but not significantly different to those seen in Trp53/ (Fig. 4G).
Tumor microenvironment
To investigate the utility of our new ID8 derivatives to study the
relationship between specific mutations within malignant cells
and the tumor microenvironment, we first stained tumors for the
presence of T lymphocytes (both CD3 and CD8) and macro-
phages (F4/80). Intraepithelial CD3þ and CD8þ cells were both
generally sparse, with no significant differences between any of
the tumor genotypes (Fig. 5A and B). However, we observed the
presence of lymphoid aggregates within Trp53/;Brca2/
tumors that were absent from both parental ID8 and Trp53/-tu-
mors (Fig. 5C; Supplementary Figs. S7 and S8). These aggregates
were composed predominantly of CD3þ cells, although CD8þ
populations were visible at the periphery (Supplementary Fig.
S9). We also observed striking and significant increases in mac-
rophage infiltration in Trp53/ tumors (Fig. 5D; Supplementary
Fig. S10). Macrophage infiltration was more variable in Trp53/;
Brca2/ tumors—median histoscore was greater than in ID8
parental tumors but lower than in Trp53/ tumors, although
neither difference was statistically significant (Fig. 5D).
We next investigated the specific role of p53 loss uponmyeloid
populations. Immunoblot array showed marked increases in the
monocyte chemoattractant CCL2, and, to a lesser extent, CCL5
and sTNFR1 in conditionedmedium from Trp53/ cells (Fig. 6A;
Supplementary Fig. S11). Immunophenotyping of disaggregated
solid tumor deposits (Fig. 6B; Supplementary Fig. S12) and ascites
(Fig. 6C; Supplementary Fig. S12) showed significant increases in
CD11bþ populations in Trp53/ tumors compared with Trp53
wild-type. Monocytic myeloid-derived suppressor cells (defined
as CD11bþLy6CþLy6G–) were the predominant myeloid popu-
lation in both tumor and ascites compared with polymorphonu-
clear (PMN) MDSC populations (CD11bþLy6CþLy6Gþ). Con-
sistent with IHC, we found significantly more F4/80-positive cells
within Trp53/ ascites, although the proportions of iNOSþ and
CD206þ cells did not alter significantly between the two geno-
types (Fig. 6D; Supplementary Figs. S13 and S14).
Discussion
Here,we show that ID8, awidely usedmurinemodel of ovarian
carcinoma, is poorly representative of HGSC, with a conspicuous
absence ofmutations in genes associated with the human disease,
and evidence of functional p53 activity. The overall mutational
burden in ID8 is low (functional variants in only 100 genes in 49
MBof sequencedDNA), which concurs with very recent data from
ID8-G7, a subline of ID8 that has been passaged in vivo (24). We
did not observe activatingmutations in common oncogenes (e.g.,
Kras, Nras, Myc, Egfr, Pik3ca) that may drive carcinogenesis in
parental ID8 cells, but we have not undertaken copy-number
analyses, and thus cannot exclude the presence of an oncogenic
amplification.
Using CRISPR/Cas9 gene editing, we generated sublines of ID8
bearing loss-of-function deletions in Trp53 and Brca2, and dem-
onstrate that these alter tumor growth in the peritoneal cavity. In
preliminary experiments, we also show that single-gene muta-
tions can alter the tumor microenvironment, with a significant
increase in immunosuppressive myeloid populations within
tumor and ascites upon loss of p53 expression, as well as the
appearance of intraepithelial lymphoid aggregates in tumors
lacking both p53 and Brca2.
Genetically engineered mouse models of HGSC have been
difficult to generate (25). Recently, two HGSC models were
described: the Drapkin lab utilized the Pax8 promoter to drive
Cre-mediated recombination of Trp53 and Pten with Brca1 or
Brca2 in mouse fallopian tube secretory epithelium. This resulted
in development of STIC lesions, and subsequent invasive tumors
in the ovary and peritoneal cavity within 20 weeks (26). By
morphology and IHC, the tumors resembled human HGSC, but
no ascites was observed, and all Pten/ mice developed endo-
metrial lesions (hyperplasia, dysplasia, or carcinoma). In addi-
tion, no transplantable cell lines have been described from these
mice. A second fallopian tube model has been described, with
SV40 large T antigen under the control of the Ovgp-1 promoter
(27, 28). Again, STIC-like lesions with p53 signatures were
described, as well as invasive tumors within the ovary. However,
no peritoneal dissemination or ascites was seen, and, again, no
lines that can be readily transplanted into nontransgenic mice
have been described. Both of these models are undoubtedly of
Figure 4.
Generation and evaluation of Trp53/;Brca2/ ID8 cells using CRISPR/Cas9.A, design of three gRNA sequences, targeted to exon 3 of Brca2 (top). Nucleotides in
red represent PAM sequences. Schematic representation of Brca2 protein (bottom). Numbers represent amino acid positions. OB, oligonucleotide binding
domain; NES, nuclear export signal. Amino acids encoded by exon 3 aremarked in red. B, parental ID8, Trp53/ cell line F3, and three Trp53/;Brca2/ cells were
treated with rucaparib (10 mmol/L), fixed and stained for gH2AX and RAD51, and counterstained with DAPI. Representative confocal microscopy images are
presented (top). RAD51 foci were counted in up to 30 untreated and rucaparib-treated cells. Bars, mean ( SD) foci per cell relative to untreated
cell; dotted line, two-fold increase in foci/cell relative to untreated cells. C, Trp53/ cell line F3 and Trp53/;Brca2/ 3.15 cells were irradiated
(10Gy), fixed and stained for gH2AX andRAD51, and counterstainedwith DAPI.D, Trp53/;Brca2/ cells are significantlymore sensitive to PARP inhibitor–induced
cytotoxicity than either parental ID8 or Trp53/ cell line F3. Each dot represents IC50 value from a single experiment performed in triplicate. Bars represent
median IC50 for three separate experiments. E, cells (5 106) were injected intraperitoneally into female C57Bl/6 mice in groups of six. Mice were killed when they
reached humane endpoints. Ascites was taken from all mice and measured. F3 CRISPR control cells are Trp53/ F3 cells exposed to PX459 encoding
Brca2 gRNA (Guide 1), but which contain no deletion in Brca2 on sequencing. F, loss of Brca2 and p53 reduces volume of ascites compared with loss of p53 alone.
 , P < 0.01. G, additional loss of Brca2 expression does not significantly alter intraperitoneal tumor proliferation, as measured by Ki67 staining. Bars on IHC
images, 100 mm. Each dot represents mean histoscore for multiple deposits (median 5; range, 1–17) per animal, normalized to tumor area.
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great importance. However, we believe that a transplantable
model, based on a single genetic background (C57Bl/6), which
recapitulates disseminated peritoneal disease with ascites and in
which multiple genotypes can potentially be rapidly investigated
in parallel, is an important adjunct to transgenic models.
One potential criticism of our models is that they arise from a
single cell line. Although other murine ovarian cancer cell lines
have been described (29), they derive from chimeric SV40 T-Ag
animals, and thus cannot be transplanted into nontransgenic
animals, which significantly reduces their utility. ID8 remains
the only murine line derived from a single nontransgenic strain
from which to base these models. A second potential criticism is
the cell of origin of ID8 itself. In the original description of ID8
(19), whole mouse ovaries were trypsinized with the aim of
Figure 5.
Loss of p53 and Brca2 expression alters immune cell infiltration in ID8 tumors. Formalin-fixed, paraffin-embedded tumors from all three genotypes (parental
ID8, Trp53/, and Trp53/;Brca2/) were stained for CD3 (A) and CD8 (B). C, the number of intraepithelial lymphoid aggregates, defined as an area
>0.1 mm2, was counted in tumors from all three genotypes. No aggregates were identified in ID8 and Trp53/ tumors. Bar, median. , P < 0.05. D, tumors
were also stained for F4/80. Bars, 100 mm. Intensity of expression was quantified as detailed in Materials and Methods. Each dot represents mean
histoscore for multiple deposits per animal, normalized to tumor area.  , P < 0.05.
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removing the OSE layer, but the exact cell of origin of ID8 is
unclear. Although the fallopian tube is undoubtedly the origi-
nating site of many HGSC, a potential ovarian origin is possible
for a subset of these tumors (13). In addition, data from the
Drapkin lab model indicated that oophorectomy reduced peri-
toneal dissemination, suggesting that the ovary plays a role in
promoting metastatic spread of fallopian tube lesions (26). Thus,
an OSE origin of ID8 does not preclude the applicability of our
new cells as a model of HGSC, and our tumors do express some
typical HGSC markers (e.g., WT1). However, the absence of Pax8
Figure 6.
Loss of p53 expression increases
CCL2 expression and induces
immunosuppressive myeloid cell
infiltration in tumor and ascites. A,
expression of chemokines in conditioned
medium was assessed using
immunoblot array. See Supplementary
Fig. S9 for complete array layout. B–D,
disaggregatedwhole tumor deposits (B)
and ascites cells (C andD)were assessed
by flow cytometry for CD4, CD8, CD11b,
Ly6G, Ly6C, F4/80, CD206, and iNOS.
Each dot represents a single tumor
deposit (minimum three deposits/
mouse) or ascites sample. Bars,
mean  SD. Trp53þ/þ populations
include ID8 parental and CRISPR control
cells lacking any Trp53 mutation.
 , P < 0.05;  , P < 0.01;  , P < 0.001.
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staining strongly suggests that ID8 is not of fallopian tube secre-
tory origin. PAX8 staining is used in the diagnosis of HGSC and is
usually strongly positive, although this is not universal (30).
Therefore, the absence of Pax8 in our ID8 models is important
to note, but is not a barrier to their use in HGSC research.
Although CRISPR/Cas9 gene editing is an extremely powerful
tool, off-target effects can occur (31, 32), which are difficult to
quantify precisely in any given model without whole-genome
sequencing. Here, we used multiple different guides and selected
at least one clone per guide. In addition, we utilized appropriate
negative controls (cells exposed to CRISPR plasmid transfection
but that do not contain mutations in target gene). The uniform
phenotypes observed in each of our models suggest strongly that
any off-target effects are not significant.
Finally, we have undertaken preliminary experiments to inves-
tigate the link between tumor-specific mutations and immune
composition in the microenvironment. Here, we show that loss
of p53 increases CCL2 expression and induces marked increases
in immunosuppressive myeloid populations both within solid
tumor deposits and ascites. CCL2 is a critical chemokine for
attraction of monocyte populations; wild-type p53 can suppress
CCL2 expression via direct binding to the CCL2 50UTR (33) and
can reduce CCL2-induced xenograft growth (34). In Trp53/
tumors, there appeared to be a bias toward monocytic MDSC
populations, which have been characterized as more immuno-
suppressive than PMN MDSC in tumor-bearing mice (35).
Intriguingly, we also observed aggregates of lymphoid cells
in tumors lacking both p53 and Brca2. The structures contained
hundreds of cells, which were predominantly CD3þ but CD8–.
Four different types of lymphoid aggregates in HGSCwere recent-
ly described, the largest of which resembled activated lymph
nodes (16), and which contain a variety of T- and B-cell
lineages, including plasma cells. The presence of plasma cells was
associated with expression of two genes, IGJ and TNFRSF17, but
was independent of mutation in BRCA1 or BRCA2. Our prelim-
inary data suggest that loss of Brca2 andp53 can lead to formation
of tertiary lymphoid aggregates, but further work, including gene
expression analysis and further flow cytometry, will be required to
elucidate this relationship. It is not clear whether these microen-
vironmental changes explain why loss of Brca2 and p53 function
results in slower intraperitoneal growth compared with p53 loss
alone. Ki67 staining suggests that there is no significant reduction
in proliferation in the Trp53/;Brca2/ tumors, suggesting that
non–cell-autonomous factors may be contributing. Certainly, in
patients with HGSC, BRCA2 mutation and the presence of intra-
tumoral lymphocytes (15) are both associated with longer overall
survival (36), although the precise mechanisms for this remain
unclear.
In summary, we have used gene editing technology to generate
transplantable murine ovarian cancer cell lines that recapitulate
critical mutations in human HGSC. Our results suggest that our
ID8 models may act as an important tool, alongside genetically
engineeredmousemodels andprimary patientmaterial, in under-
standing the complexities of HGSC biology. Further mutants are
under construction, and all our ID8 derivatives are freely available
to other researchers.
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